After a successful meeting with the Food and Drug Administration last month, biopharmaceutical firm Palatin Technologies got the go-ahead to file a biologics license application this summer for its monoclonal antibody infection imaging agent,
After a successful meeting with the Food and Drug Administration last month, biopharmaceutical firm Palatin Technologies got the go-ahead to file a biologics license application this summer for its monoclonal antibody infection imaging agent, LeuTech. The company met with the FDAs Center for Biologic Evaluation and Research in Rockville, MD, and the agency reviewed Palatins phase III trial data for LeuTech for the diagnosis of equivocal appendicitis. Palatin hopes LeuTech will be available for sale by mid-summer 2000.
The FDAs permission to proceed further enhances the Princeton, NJ, companys R&D momentum, as it comes on the heels of the companys May 17 announcement that it had signed a letter of intent for a marketing alliance with St. Louis-based Mallinckrodt (SCAN 5/26/99).
© 1999 Miller Freeman, Inc.All rights reserved.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.